COMPASS Pathways (Nasdaq:CMPS) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

CMPS Aktienübersicht

COMPASS Pathways plc ist im Vereinigten Königreich und in den Vereinigten Staaten als Unternehmen im Bereich der psychischen Gesundheit tätig.

Über das Unternehmen

CMPS fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Belohnungen

Risikoanalyse

COMPASS Pathways plc Wettbewerber

Korro Bio

NasdaqCM:KRRO

US$391.2m

Fate Therapeutics

NasdaqGM:FATE

US$442.8m

Altimmune

NasdaqGM:ALT

US$459.4m

Editas Medicine

NasdaqGS:EDIT

US$446.6m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for COMPASS Pathways
Historical stock prices
Current Share Price	US$6.84
52 Week High	US$12.75
52 Week Low	US$5.01
Beta	2.33
1 Month Change	-15.76%
3 Month Change	-30.17%
1 Year Change	-13.20%
3 Year Change	-81.66%
5 Year Change	n/a
Change since IPO	-76.41%

Aktuelle Nachrichten und Updates

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

May 23

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

Apr 25

Recent updates

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

May 23

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

Apr 25

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

Feb 08

Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Dec 06

Booker again pushes for easier access to psychedelics for terminally ill patients

Oct 19

Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

Aug 13

Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront

Jan 01

Compass Pathways: Risky And Overvalued

Dec 18

What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?

Dec 18

COMPASS Pathways: Risky But Can Pay Back Generously

Dec 14

Compass Pathways: An Overvalued Psychedelic Company With A Single Mediocre Drug

Nov 23

COMPASS Pathways ADS reports Q3 results

Nov 12

Aktionärsrenditen

	CMPS	US Biotechs	US Markt
7D	-8.4%	1.9%	1.3%
1Y	-13.2%	6.7%	21.0%

Preisvolatilität

Is CMPS's price volatile compared to industry and market?
CMPS volatility
CMPS Average Weekly Movement	9.0%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.8%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	2.8%

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2020	186	Kabir Nath	compasspathways.com

COMPASS Pathways plc ist im Vereinigten Königreich und in den Vereinigten Staaten als Unternehmen im Bereich der psychischen Gesundheit tätig. Es entwickelt COMP360, eine Psilocybin-Therapie, die sich in klinischen Studien der Phase III zur Behandlung von behandlungsresistenten Depressionen und in klinischen Studien der Phase II zur Behandlung von posttraumatischer Belastungsstörung und Anorexia nervosa befindet. Das Unternehmen war früher unter dem Namen COMPASS Rx Limited bekannt und änderte im August 2020 seinen Namen in COMPASS Pathways plc.

COMPASS Pathways plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von COMPASS Pathways im Vergleich zum Marktanteil des Unternehmens?
CMPS grundlegende Statistiken
Marktanteil	US$436.95m
Gewinn(TTM)	-US$129.44m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-3.6x

Kurs-Gewinn-Verhältnis

Ist CMPS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
CMPS Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$129.44m
Umsatz	-US$129.44m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-1.89
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	11.2%

Wie hat sich CMPS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

CMPS Aktienübersicht

Belohnungen

Risikoanalyse

COMPASS Pathways plc Wettbewerber

NasdaqCM:KRRO

US$391.2m

NasdaqGM:FATE

US$442.8m

NasdaqGM:ALT

US$459.4m

NasdaqGS:EDIT

US$446.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Insider recently sold US$123k worth of stock

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

COMPASS Pathways plc, Annual General Meeting, May 09, 2024

Price target decreased by 8.1% to US$39.50

Recent updates

Insider recently sold US$123k worth of stock

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder

COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?

COMPASS Pathways plc, Annual General Meeting, May 09, 2024

Price target decreased by 8.1% to US$39.50

Chairman & Co-founder notifies of intention to sell stock

New major risk - Shareholder dilution

Co-Founder & Director recently sold US$305k worth of stock

COMPASS Pathways plc to Report Q4, 2023 Results on Feb 29, 2024

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

Chairman & Co-founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

COMPASS Pathways plc Announces Management Changes

COMPASS Pathways plc Announces Chief Financial Officer Changes

Price target decreased by 7.4% to US$42.38

COMPASS Pathways plc to Report Q3, 2023 Results on Nov 02, 2023

Compass Pathways plc Announces Executive Changes, Effective November 3 ,2023

Compass Pathways plc Announces the Appointment of Daphne Karydas to Its Board of Directors

New major risk - Revenue and earnings growth

New minor risk - Share price stability

COMPASS Pathways plc announced that it expects to receive $125 million in funding from a group of investors

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New major risk - Financial position

Compass Pathways Announces Resignation of Ekaterina Malievskaia as Chief Innovation Officer, Effective from June 16, 2023

Compass Pathways plc Announces Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of Comp360 Psilocybin Therapy to Be Presented At Asco 2023

COMPASS Pathways plc to Report Q1, 2023 Results on May 11, 2023

COMPASS Pathways plc Announces COMP360 Psilocybin Therapy Shows Potential in Open-Label Study in Type II Bipolar Disorder Presented At ACNP

Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth

Price target decreased to US$55.09

Booker again pushes for easier access to psychedelics for terminally ill patients

Price target decreased to US$60.22

Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation

COMPASS Pathways And The Trillion Dollar Opportunity

Price target decreased to US$67.67

COMPASS Pathways ADS Q2 2022 Earnings Preview

COMPASS Pathways plc Launches Phase II Clinical Trial of Psilocybin Therapy in Anorexia Nervosa

COMPASS Pathways plc to Report Q2, 2022 Results on Aug 04, 2022

Compass Pathways Appoints Kabir Nath as Chief Executive Officer

COMPASS Pathways names new CEO

Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy

COMPASS Pathways plc Presents Largest Ever Study of Psilocybin Therapy, At American Psychiatric Association Annual Meeting

Price target decreased to US$70.90

Co-Founder notifies of intention to sell stock

Compass Pathways plc Announces Positive Data Demonstrating the Potential of COMP360 Psilocybin Therapy in Anorexia Nervosa and Severe Treatment-Resistant Depression Has Been Presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from Two Investigator-Initiated Studies

COMPASS Pathways plc to Report Q1, 2022 Results on May 10, 2022

We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely

COMPASS Pathways plc, Annual General Meeting, Jun 16, 2022

COMPASS Pathways plc Announces Jason Camm Not to Stand for Re-Election as A Director

Checking In On Compass Pathways

Consensus forecasts updated

Price target decreased to US$75.60

COMPASS Pathways plc to Report Q4, 2021 Results on Feb 24, 2022

COMPASS Pathways plc Study of 89 Healthy Participants Published in Journal of Psychopharmacology

General Counsel & Chief Legal Officer notifies of intention to sell stock

We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth

Compass Pathways Announces Positive Outcome of 25Mg Comp360 Psilocybin Therapy as Adjunct to Ssri Antidepressants in Open-Label Treatment-Resistant Depression Study

Compass Pathways Announces Further Positive Results from Phase IIb Trial of Investigational Comp360 Psilocybin Therapy for Treatment-Resistant Depression

Erträge & Einnahmen